Mumbai, Nov. 10 -- Olaparib is indicated for the treatment of ovarian, breast, pancreatic, and prostate cancers in patients with specific genetic mutations, particularly those in the BRCA gene or other homologous recombination repair (HRR) genes. The drug will be manufactured at Zydus Lifesciences' SEZ facility.

The approved product is bioequivalent to Lynparza Tablets (100 mg and 150 mg), which recorded annual sales of $1,379.4 million in the United States, according to IQVIA MAT data for September 2025.

With this approval, Zydus Lifesciences' total tally now stands at 426 approvals, from a cumulative 487 ANDA filings since the company began the process in FY 2003-04.

The Zydus Group with an overarching purpose of empowering people wi...